Trial reportInternational ophthalmology2025
Safety and efficacy of ranibizumab combined with dexamethasone intravitreal implant versus ranibizumab monotherapy for macular edema secondary to retinal vein occlusion: a 12-month prospective, randomized study.
Trial report in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Geometry-Based Intravitreal Pharmacokinetics: A Theoretical Pharmacokinetic Modeling Study Using Triamcinolone Acetonide and Vancomycin as Representative Intravitreal Agents.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeTo compare the 1-year efficacy and safety of intravitreal ranibizumab monotherapy against a combination therapy of ranibizumab and a dexamethasone intravitreal implant for treating macular edema secondary to retinal vein occlusion (RVO-ME). The primary research question assessed whether combination therapy resulted in superior improvements in best-corrected visual acuity (BCVA) and central macular thickness (CMT) compared to monotherapy.
methodsThis prospective, randomized, controlled study included 93 patients with RVO-ME. Patients were randomly assigned to either the ranibizumab monotherapy group (RBZ, n = 47) or the combination therapy group (RBZ + DEX, n = 46). The RBZ group received monthly ranibizumab for 3 months, while the RBZ + DEX group received ranibizumab at baseline, a dexamethasone implant 15 days later, and then ranibizumab for months 2 and 3. After the initial phase, both groups received pro-re-nata (PRN) retreatment based on specific criteria over a 12-month follow-up period.
resultsAt 52 weeks, both treatments significantly improved BCVA and CMT from baseline. The combination therapy group demonstrated significantly better BCVA improvement at weeks 4, 12, 26, and 52. The RBZ + DEX group also required significantly fewer injections and follow-up visits and had a longer mean retreatment interval. Ocular hypertension was more common in the combination group but was managed with medication. Subgroup analysis showed that the benefits of combination therapy on both visual and anatomical outcomes were more pronounced in patients with branch RVO (BRVO).
conclusionCombination therapy with ranibizumab and a dexamethasone implant provides superior visual outcomes and reduces the treatment burden compared to ranibizumab monotherapy for RVO-ME over 12 months. The safety profile was favorable, though monitoring for ocular hypertension is necessary. These benefits are particularly significant for patients with BRVO-ME.
Indexed as
Identifiers
41128968What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.